Jin Qiao Biological Technology Co., Ltd.
Jin Qiao Biological Technology Co., Ltd.

Lactobacillus rhamnosus MP108

Origin:

Isolated from healthy infant’s intestinal tract and suitable for Chinese. No domestication or induced mutation.

Patents:

Novel Lactobacillus strains and their uses for modulating immune response.
I1429444
ZL201310269240.7
ZL201110404611.9

Lactobacillus paracasei MP137

Origin:

From healthy infants and young children intestinal screening, screening out in line with the Chinese probiotics, without any domestication, mutagenesis method to change the strain.

Patents:

Novel Lactobacillus strains and their uses for modulating immune response.
I1429444 / ZL201310269240.7 / ZL201110404611.9
Application of lactic acid bacteria strain in immune
response regulationZL2 01310481560.9

Jin Qiao Biological Technology Co., Ltd.
Jin Qiao Biological Technology Co., Ltd.

Lactobacillus rhamnosus F-1

Origin:

Isolated from healthy female reproductive tract and suitable for Chinese. No domestication or induced mutation.

Patents:

Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus.
Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus.I1451871 / ZL201110179138.9 / US9011839 B2
Anti-vaginitis food composition and pharmaceutical composition containing lactobacillus.I452353
Food, oral cleaning and pharmaceutical composition with strains of lactic acid bacteria for inhibiting of oral pathogens. I639389

Bifidobacterium animalis subsp. lactis CP-9

Origin:

Isolated from breast milk by Bioflag RD and suitable for Chinese. No domestication or induced mutation.

Patents:

Anti-obesity strain of lactic acid bacteria and uses in food and pharmaceutical compositions
I572713 / ZL 201510074689.

Jin Qiao Biological Technology Co., Ltd.
Jin Qiao Biological Technology Co., Ltd.

Lactobacillus paracasi ET-66

Origin:

Isolated from breast milk by Bioflag RD and suitable for Chinese. No domestication or induced mutation.

Patents:

Food, oral cleaning and pharmaceutical composition with strains of lactic acid bacteria for inhibiting of oral pathogens.
I639389

1.  Use of a fast and efficient co-culture model to evaluate anti-inflammatory and barrier-reinforcing effects of commercial Lactobacillus strains. The 6th Congress of Asian Society for Pediatric Research & 51st Annual Meeting Of Taiwan Pediatric Association, April 15-18, 2010.

2.  Evaluation of Efficacy and Safety of Lactobacillus rhamnosus as an Add-on Therapy in Children(7-12 Years Old) with Perennial Allergic Rhinitis: An 8 Weeks, Double-blind, Randomized, Placebo-controlled Study with a 4-week Follow-up. ISSN 1608-8115 ACTA PAEDIATRICA TAIWANICA, November 2012, Vol. 53, Supplement.

3.  Evaluation of Efficacy and Safety of Lactobacillus rhamnosus in Children Aged 4-48 Months with Atopic Dermatitis: A 8-Week, Double-Blind, Randomized, Placebo-Controlled Study.

4.  Clinical effects for patients with rotaviral enteritis by Bifidobacterium combined with Lactobacillus rhamnosus and the influence on the immune function. Medical Innovation of China 2016 Vol.13, No.6 p.59-61.

5.  Effects of supplemented Bifidobacterium and Lactobacillus acidophilus triple living bacteria preparation on intestinal flora after intestinal surgery. CHINA MODERN MEDICINE Vol. 24 No. 5 February 2017.

6.  Clinical observation of active probiotics in the treatment of allergic rhinitis and analysis of its effect on immunoregulation. CHINA MODERN DOCTOR Vol. 55 No. 5 February 2017.

7.  Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4-48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study. Journal of Microbiology, Immunology and Infection. Volume 50, Issue 5, October 2017, p. 684-692

8.  A clinical study on early application of lactobacillus tetravaccine in preventing allergic diseases of infants. Practical Journal of Clinical Medicine Vol.15 No.4 July 2018.

9.  Lactobacillus rhamnosus MP108: Toxicological evaluation. J Food Sci. 2021 Jan;86(1):228-241

Leave contact information, get information

Submit Message

1.  Evaluation of Efficacy and Safety of Lactobacillus Paracasei Capsule as an Add-on Therapy in Children(6-13 Years Old) with Perennial Allergic Rhinitis: A 12-week, Double-blind, Randomized, Placebo-Controlled Study.

2.  Evaluation of the Effect of Lactobacillus paracasei (HF.A00232) in Children (6–13 years old) with Perennial Allergic Rhinitis: A 12-week, Double-blind, Randomized, Placebo-controlled Study[J]. Pediatrics & Neonatology, 2014, 55(3):181-188.

3.  A clinical study on early application of lactobacillus tetravaccine in preventing allergic diseases of infants. Practical Journal of Clinical Medicine Vol.15 No.4 July 2018.

1.  Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization. Journal of Food Science 2011; Vol.76, Nr.5: p.M260-M267.

2.  The potential for probiotics to modulate inflammatory of oral and throat by in vitro and animal model. The 6th Asian Conference on Lactic Acid Bacteria 2011; P-AM11-78.

3.  Inhibition of in vitro growth of pathogens to protect human mucosae by probiotics. The 7th International Symposium on Lactic Acid Bacteria and Health. 2012; P2-18.

4.  Potential of probiotic strains to modulate the inflammatory responses of epithelial and immune cells in vitro. New Microbiologica 2013; 36: p.167-179.

5.  Comparison of the inhibition effect of lactic acid bacteria fermentation metabolites on different vaginal pathogens and developing gynecological probiotic products. CIFST. 2017.

6.  Inhibitory effects of viable and heat-killed lactic acid bacteria against different vaginal pathogens: toward development of gynecological probiotics. IUMS. 2017.

7.  Applications of lactic acid bacteria to inhibit the growth of fish pathogens and improve the feed conversion rate in aquaculture. IUMS. 2017.

8.  Clinical study of Lactobacillus salivarius, Lactobacillus acidophilus and Lactobacillus plantarum triple viable capsules combined with triple therapy for Helicobacter pylori eradication.Medical Innovation of China. 2017; 14(10): p.036-039.

9.  Clinical effect of probiotics freeze-Dried Powder combined with bis-muth-containing quadruple therapy in the treatment of Helicobacter pylori infection.  CHINA MODERN MEDICINE Vol. 25 No. 24 Aug. 2018. p.155-7.

10.  A clinical study on early application of lactobacillus tetravaccine in preventing allergic diseases of infants. PRACTICAL JOURNAL OF CLINICAL MEDICINE Vol. 15 No. 4 July 2018, p.71-3.

1.  Inhibition of in vitro growth of pathogens to protect human mucosae by probiotics. CIFST. 2012; P2-18.
2.  Effects of two novel Bifidobacteria strain on obesity and lipid levels. The 6th International Conference on Food Factors 2015; P-0483.

3.  Inhibitory effect of viable and heat-killed lactic acid bacteria against different vaginal pathogens : toward development of gynecological probiotics. 15th International Congress of Mycology and Eukaryotic Microbiology 2017; PO 287.

4.  Applications of lactic acid bacteria to inhibit the growth of fish pathogens and improve the feed conversion rate in aquaculture. 15th International Congress of Mycology and Eukaryotic Microbiology 2017; PO 288.

5.  Functional characterization and applicant of probiotic strains advantages on oral health care. The 13th international symposium on lactic acid bacteria and health 2018.

6.  Clinical research on the effects of probiotics on regulation of body weight. 14th Annual Meeting of Chinese Institute of Food Science and Technology, 2019 (CIFST) 

7.  Bacteriostatic activities of lactic acid bacteria against extended-spectrum β-lactamase(ESBL)-producing Escherichia coli. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):3-4.

8.  Bacteriostatic abilities of viable and heat-killed lactic acid bacteria against group B Streptococcus. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):12-13.

9.  Assessment of bacteriostatic activities of viable and non-viable lactic acid bacteria against methicillin-resistant Staphylococcus aureus. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):14-15.

10.  Antibacterial activity of viable and heat-killed probiotic strains against oral pathogens. Lett Appl Microbiol. 2020 Apr;70(4):310-317.

 

1.  Functional characterization and applicant of probiotic strains advantages on oral health care. The 13th international symposium on lactic acid bacteria and health 2018.

2.  Antibacterial activity of viable and heat-killed probiotic strains against oral pathogens. Lett Appl Microbiol. 2020 Apr;70(4):310-317.

Jin Qiao Biological Technology Co., Ltd.